All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.

The AML Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

How could new treatment combinations improve outcomes in TP53 mutant AML?

During the Society of Hematologic Oncology (SOHO) 2021 Annual Meeting, the AML Hub spoke to Naval Daver, MD Anderson Cancer Center, Houston, US. We asked, How could new treatment combinations improve outcomes in TP53 mutant AML?

How could new treatment combinations improve outcomes in TP53 mutant AML?

Daver begins by discussing a recent study that analyzed patients on hypomethylating agents (HMA) versus cytarabine based regimens. He highlights that HMA based therapy maintained better response rates regardless of TP53 variant allele frequency, unlike the cytrabine regimen. He goes on to outline further HMA regimens, such as combinations with venetoclax. He then discusses immune therapies such as magrolimab and their outcomes. Finally, he explains the results of the recent study using APR-246 and the promising activity of natural killer (NK) and NK CAR-T cell based therapies.

 

Share: